Logo image of GRTX

GALERA THERAPEUTICS INC (GRTX) Stock Fundamental Analysis

NASDAQ:GRTX - Nasdaq - US36338D1081 - Common Stock - Currency: USD

0.145  -0.07 (-32.59%)

After market: 0.1379 -0.01 (-4.9%)

Fundamental Rating

1

Overall GRTX gets a fundamental rating of 1 out of 10. We evaluated GRTX against 549 industry peers in the Biotechnology industry. Both the profitability and financial health of GRTX have multiple concerns. GRTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GRTX has reported negative net income.
In the past year GRTX has reported a negative cash flow from operations.
In the past 5 years GRTX always reported negative net income.
GRTX had a negative operating cash flow in each of the past 5 years.
GRTX Yearly Net Income VS EBIT VS OCF VS FCFGRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

GRTX has a worse Return On Assets (-232.80%) than 91.51% of its industry peers.
Industry RankSector Rank
ROA -232.8%
ROE N/A
ROIC N/A
ROA(3y)-154.7%
ROA(5y)-120.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRTX Yearly ROA, ROE, ROICGRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRTX Yearly Profit, Operating, Gross MarginsGRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRTX has more shares outstanding
Compared to 5 years ago, GRTX has more shares outstanding
Compared to 1 year ago, GRTX has a worse debt to assets ratio.
GRTX Yearly Shares OutstandingGRTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GRTX Yearly Total Debt VS Total AssetsGRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -36.96, we must say that GRTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -36.96, GRTX is doing worse than 93.24% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.96
ROIC/WACCN/A
WACCN/A
GRTX Yearly LT Debt VS Equity VS FCFGRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 7.54 indicates that GRTX has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.54, GRTX is doing good in the industry, outperforming 67.76% of the companies in the same industry.
A Quick Ratio of 7.54 indicates that GRTX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.54, GRTX is in the better half of the industry, outperforming 67.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.54
GRTX Yearly Current Assets VS Current LiabilitesGRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

GRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.27%, which is quite impressive.
EPS 1Y (TTM)55.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.30% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.72%
EPS Next 2Y25.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRTX Yearly Revenue VS EstimatesGRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 20M 40M 60M 80M 100M
GRTX Yearly EPS VS EstimatesGRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRTX Price Earnings VS Forward Price EarningsGRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRTX Per share dataGRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

GRTX's earnings are expected to grow with 25.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GALERA THERAPEUTICS INC

NASDAQ:GRTX (6/3/2024, 8:18:13 PM)

After market: 0.1379 -0.01 (-4.9%)

0.145

-0.07 (-32.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/bmo
Earnings (Next)08-12 2024-08-12/bmo
Inst Owners0.66%
Inst Owner Change0%
Ins Owners49.52%
Ins Owner Change0%
Market Cap7.89M
Analysts45.71
Price Target0.38 (162.07%)
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS-2.48
TBVpS-2.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -232.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.7%
ROA(5y)-120.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.54
Altman-Z -36.96
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)28.65%
Cap/Depr(5y)88.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.89%
EPS Next Y31.72%
EPS Next 2Y25.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year110.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.72%
OCF growth 3YN/A
OCF growth 5YN/A